{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:14:29Z","timestamp":1770970469460,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Colombiana de Psiquiatr\u00eda"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.rcp.2015.05.008","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T22:12:42Z","timestamp":1435097562000},"page":"220-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluaci\u00f3n y seguimiento metab\u00f3lico del paciente con diagn\u00f3stico de esquizofrenia"],"prefix":"10.1016","volume":"44","author":[{"given":"Gabriel Fernando","family":"Oviedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"G\u00f3mez Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Boh\u00f3rquez Pe\u00f1aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Garc\u00eda Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Eduardo","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"V\u00e9lez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcp.2015.05.008_bib0205","first-page":"472","article-title":"The American Psychiatric Publishing Textbook of Schizophrenia","author":"Lieberman","year":"2007","journal-title":"American Psychiatric Pub"},{"issue":"5","key":"10.1016\/j.rcp.2015.05.008_bib0210","first-page":"251","article-title":"Consenso sobre la salud f\u00edsica del paciente con esquizofrenia de las Sociedades Espa\u00f1olas de Psiquiatr\u00eda y de Psiquiatr\u00eda Biol\u00f3gica","volume":"36","author":"S\u00e1iz Ruiz","year":"2008","journal-title":"Actas Esp Psiquiatr."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.008_bib0215","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.008_bib0220","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.psc.2007.07.006","article-title":"Hematologic problems in psychosomatic medicine","volume":"30","author":"Becker","year":"2007","journal-title":"Psychiatr Clin North Am."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.008_bib0225","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0033-3182(99)71206-5","article-title":"Hematologic side effects of psychotropics","volume":"40","author":"Oyesanmi","year":"1999","journal-title":"Psychosomatics."},{"issue":"6","key":"10.1016\/j.rcp.2015.05.008_bib0230","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.rcp.2015.05.008_bib0235","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2013.13040447","article-title":"Bipolar disorder, schizophrenia, and metabolic syndrome","volume":"170","author":"Bartoli","year":"2013","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rcp.2015.05.008_bib0240","series-title":"Metabolic Syndrome and Psychiatric Illness: Interactions, Pathophysiology, Assessment and Treatment","first-page":"221","author":"Mendelson","year":"2008"},{"issue":"1","key":"10.1016\/j.rcp.2015.05.008_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.008_bib0250","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/jhm.691","article-title":"extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?","volume":"5","author":"Meyer-Massetti","year":"2010","journal-title":"J Hosp Med Off Publ Soc Hosp Med."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.008_bib0255","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881107075509","article-title":"Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia","volume":"21","author":"Barnett","year":"2007","journal-title":"J Psychopharmacol Oxf Engl."},{"issue":"6","key":"10.1016\/j.rcp.2015.05.008_bib0260","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur Psychiatry J Assoc Eur Psychiatr."},{"issue":"2","key":"10.1016\/j.rcp.2015.05.008_bib0265","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.bp.110.084665","article-title":"Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation","volume":"199","author":"De Hert","year":"2011","journal-title":"Br J Psychiatry J Ment Sci."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.008_bib0270","first-page":"114","article-title":"Delphi consensus on the physical health of patients with schizophrenia: evaluation of the recommendations of the Spanish Societies of Psychiatry and Biological Psychiatry by a panel of experts","volume":"40","author":"Bobes-Garc\u00eda","year":"2012","journal-title":"Actas Esp Psiquiatr."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.008_bib0275","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/08039488.2010.500397","article-title":"Swedish clinical guidelines--prevention and management of metabolic risk in patients with severe psychiatric disorders","volume":"64","author":"Gothefors","year":"2010","journal-title":"Nord J Psychiatry. octubre de"},{"key":"10.1016\/j.rcp.2015.05.008_bib0280","article-title":"Ministry of Health, Malaysia","year":"2009","journal-title":"Management of Schizophrenia in, adults."},{"issue":"6 suppl","key":"10.1016\/j.rcp.2015.05.008_bib0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0269881105058986","article-title":"Metabolic and lifestyle issues and severe mental illness - new connections to well-being?","volume":"19","year":"2005","journal-title":"J., Psychopharmacol, (Oxf)."},{"key":"10.1016\/j.rcp.2015.05.008_bib0405","unstructured":"Scottish Intercollegiate Guidelines Network. SIGN 50, A guideline developer's handbook. Edinburgh, 2011 [Internet]. 2011. Recuperado a partir de: http:\/\/www.sign.ac.uk\/pdf\/sign50.pdf."},{"issue":"4","key":"10.1016\/j.rcp.2015.05.008_bib0410","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1 Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.rcp.2015.05.008_bib0415","unstructured":"Ministerio de la Protecci\u00f3n Social - COLCIENCIAS. Gu\u00eda Metodol\u00f3gica para la elaboraci\u00f3n de Gu\u00edas Atenci\u00f3n Integral en el Sistema General de Seguridad Social en Salud Colombiano [Internet]. Bogot\u00e1. Colombia; 2010. Recuperado a partir de: http:\/\/www.minsalud.gov.co\/salud\/Documents\/Gu%C3%ADa%20Metodol%C3%B3gica%20para%20la%20elaboraci%C3%B3n%20de%20gu%C3%ADas.pdf."},{"key":"10.1016\/j.rcp.2015.05.008_bib0420","unstructured":"National Collaborating Centre for Mental Health, commissioned by the National Institute for Health & Clinical Excellence. Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (updated edition). National Clinical Guideline Number 82 [Internet]. Printed in Great Britain. Stanley Hunt.; 2010. Recuperado a partir de: http:\/\/www.nice.org.uk\/."},{"key":"10.1016\/j.rcp.2015.05.008_bib0310","unstructured":"Ministerio de Salud y Protecci\u00f3n Social - Colciencias - IETS. Gu\u00eda de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico, tratamiento e inicio de la rehabilitaci\u00f3n psicosocial de los adultos con esquizofrenia [Internet]. 2014. Recuperado a partir de: http:\/\/gpc.minsalud.gov.co."},{"issue":"3","key":"10.1016\/j.rcp.2015.05.008_bib0315","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1176\/appi.ajp.2012.12050599","article-title":"Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study","volume":"170","author":"Crump","year":"2013","journal-title":"Am J Psychiatry."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.008_bib0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.nmd.0000105996.62105.07","article-title":"Serious cardiovascular events and mortality among patients with schizophrenia","volume":"192","author":"Enger","year":"2004","journal-title":"J Nerv Ment Dis."},{"issue":"9","key":"10.1016\/j.rcp.2015.05.008_bib0325","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study","volume":"66","author":"Henderson","year":"2005","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.008_bib0330","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.schres.2009.12.016","article-title":"Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study","volume":"117","author":"Bresee","year":"2010","journal-title":"Schizophr Res."},{"issue":"8","key":"10.1016\/j.rcp.2015.05.008_bib0335","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.pnpbp.2011.07.003","article-title":"Screening for diabetes using monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a 1-year follow-up study","volume":"35","author":"Kusumi","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"7","key":"10.1016\/j.rcp.2015.05.008_bib0340","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/aje\/kwj289","article-title":"Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia","volume":"164","author":"Lambert","year":"2006","journal-title":"Am J Epidemiol."},{"issue":"9","key":"10.1016\/j.rcp.2015.05.008_bib0345","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.rcp.2015.05.008_bib0350","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00004850-200501000-00007","article-title":"Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure","volume":"20","author":"Sacchetti","year":"2005","journal-title":"Int Clin Psychopharmacol."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.008_bib0355","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0447.2008.01158.x","article-title":"Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia","volume":"117","author":"Saddichha","year":"2008","journal-title":"Acta Psychiatr Scand."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.008_bib0360","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euroneuro.2005.11.002","article-title":"Diabetes mellitus and antipsychotic treatment in the United Kingdom","volume":"16","author":"Carlson","year":"2006","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.rcp.2015.05.008_bib0365","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia?. A comparative meta-analysis of first episode, untreated and treated patients","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull."},{"issue":"5","key":"10.1016\/j.rcp.2015.05.008_bib0370","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4088\/JCP.v65n0519","article-title":"Cardiovascular disease in patients with schizophrenia in Saskatchewan","volume":"65","author":"Curkendall","year":"2004","journal-title":"Canada. J Clin Psychiatry."},{"issue":"17","key":"10.1016\/j.rcp.2015.05.008_bib0375","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation."},{"issue":"2 Pt 2","key":"10.1016\/j.rcp.2015.05.008_bib0380","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3109\/15622970802503334","article-title":"The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study","volume":"11","author":"Koponen","year":"2010","journal-title":"World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry."},{"issue":"6","key":"10.1016\/j.rcp.2015.05.008_bib0385","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","article-title":"Novel antipsychotics: comparison of weight gain liabilities","volume":"60","author":"Wirshing","year":"1999","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"10.1016\/j.rcp.2015.05.008_bib0390","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.pnpbp.2010.04.003","article-title":"The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine","volume":"34","author":"Chiu","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rcp.2015.05.008_bib0395","unstructured":"Abou-Setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, Armijo-Olivo S, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 [citado 4 de julio de 2013]. Recuperado a partir de: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK107254\/."},{"issue":"7","key":"10.1016\/j.rcp.2015.05.008_bib0400","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: Comparative effectiveness of first-generation versus second-generation medications: A systematic review and meta-analysis","volume":"157","author":"Hartling","year":"2012","journal-title":"Ann Intern Med."}],"container-title":["Revista Colombiana de Psiquiatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745015000700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745015000700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T10:28:29Z","timestamp":1537525709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034745015000700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0034745015000700"],"URL":"https:\/\/doi.org\/10.1016\/j.rcp.2015.05.008","relation":{},"ISSN":["0034-7450"],"issn-type":[{"value":"0034-7450","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluaci\u00f3n y seguimiento metab\u00f3lico del paciente con diagn\u00f3stico de esquizofrenia","name":"articletitle","label":"Article Title"},{"value":"Revista Colombiana de Psiquiatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcp.2015.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Asociaci\u00f3n Colombiana de Psiquiatr\u00eda. Published by Elsevier Spain S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}